Using their innovative TransCon prodrug technology platform, Ascendis Pharma aims to create new and potentially best-in-class therapies by identifying new opportunities addressing areas of high unmet medical need. The TransCon technology platform is applicable to all drug classes and is currently being used to create superior prodrugs of proteins, peptides, and small molecules. The prodrugs are new chemical entities with new patent life, and the product development process is de-risked as the prodrugs release the active component in its native and unmodified form, maintaining the original drug’s well-known mode of action. Ascendis Pharma currently has three independent endocrinology rare disease product candidates in clinical development and is advancing programs in Oncology and Ophthalmology.